SBI Securities’s Adial Pharmaceuticals ADIL Stock Holding History

SBI Securities’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120	Hold	47	–	–	﹤0.01%	3465
2026 Q1	$84	Buy	47 +1	+2%	+$4	﹤0.01%	3453
2025 Q4	$255	Sell	46 -10	-18%	-$81	﹤0.01%	3135
2025 Q3	$493	Buy	56 +3	+6%	+$29	﹤0.01%	2972
2025 Q2	$398	Buy	53 +16	+43%	+$242	﹤0.01%	3055
2025 Q1	$588	Hold	37	–	–	﹤0.01%	2805
2024 Q4	$946	Buy	+37	New	+$963	﹤0.01%	2633

Other funds holding ADIL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities's ADIL Position: Q2 2026 in Review

SBI Securities held its Adial Pharmaceuticals (ADIL) position steady in Q2 2026 at 47 shares worth $120. The position accounts for ﹤0.01% of the portfolio, ranked #3465.

SBI Securities first reported a position in ADIL in Q4 2024 and has held it in 7 quarters since. The position peaked at $946 in Q4 2024. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

SBI Securities held 47 shares of Adial Pharmaceuticals worth $120 as of Q2 2026.
SBI Securities left its Adial Pharmaceuticals share count unchanged in Q2 2026.
Adial Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3465 holding.
SBI Securities first reported a position in Adial Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Adial Pharmaceuticals position peaked at $946 in Q4 2024.
17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.